LUNGevity Foundation and the American Society for Radiation Oncology (ASTRO) are partnering to support radiation oncology research — an important area of study for the early detection and treatment of lung cancer.
“Radiation oncology plays a central role in the treatment of lung cancer, irrespective of stage and histology of the disease,” explained Upal Basu Roy, PhD, MPH, LUNGevity’s executive director of research. “Over 60% of patients with a lung cancer diagnosis will receive at least some form of radiation therapy with either curative or palliative intent. It is critical to foster young talent in the field of radiation oncology to ensure the vibrancy and sustainability of the field. We are pleased to partner with ASTRO given our joint commitment to supporting junior investigators interested in practicing radiation oncology.”
The ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant fosters and develops the research careers of residents and fellows interested in radiation oncology-related basic, translational, and/or clinical research to benefit patients with lung cancer. This is a $25,000 one-year award.
“Through this partnership with LUNGevity, ASTRO reinforces our commitment to continue to develop the radiation oncology workforce. We are delighted to partner with LUNGevity Foundation in our support of junior investigators,” noted H Timothy Hsiao, PhD, director, Department of Scientific Affairs at ASTRO. “We appreciate LUNGevity’s gold standard vetting process, on par with the standards used by the National Institutes of Health, to ensure that the best and brightest young researchers at the forefront of radiation oncology research are given a chance to establish themselves.”
The deadline to submit an application for the ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant is March 24, 2023. The award announcement will be made in early summer 2023. For more information about this award, visit www.lungevity.org/astro-grant.Back To Top
LUNGevity, ASTRO to Offer Lung Cancer Research Grant. Appl Rad Oncol.